- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02223143
A Registration Study for Dyslipidemia
A Registration Study for Primary and Secondary Prevention in Dyslipidemic Taiwanese
Study Overview
Status
Conditions
Detailed Description
This is a registry study to define the status of lipid lowering therapy in Taiwan and the effect of LLT on CVD morbidity and mortality in a large population of patients receiving primary or secondary prevention therapy. The medications will only depend on the decision made by the primary care physicians. The patient or physician can decide to be withdrawn from this registry at any time because of any reason.
All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place yearly thereafter for 5 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- NTUH
-
Contact:
- C C W
- Phone Number: 88560 886-2-23123456
- Email: chauchungwu@ntu.edu.tw
-
Sub-Investigator:
- W T K
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- One with atherosclerotic vascular diseases
- One without ASVD but with at least 1 CV risk factor
- Apparent healthy persons
Exclusion Criteria:
- One with hemodynamically significant valvular or congenital heart disease
- One with any non-cardiovascular diseases which may affect prognosis
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time to first occurrence of a major cardiovascular event
Time Frame: up to 5 years
|
The major CV (cardiovascular) event will be defined as CV death, hospitalization for nonfatal MI (myocardial infarction) or stroke, or cardiac arrest with resuscitation
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite cardiovascular outcome
Time Frame: up to 5 years
|
The composite cardiovascular (CV) outcome will be any CV events (any major CV events plus hospitalization for any revascularization procedure, unstable angina, or congestive heart failure, and peripheral arterial disease, defined as new clinical diagnosis or hospitalization for such disease).
In addition, individual components of the composite end points will be also prespecified as secondary outcomes, as will all-cause mortality.
|
up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The biochemistry change
Time Frame: up to 5 years
|
The tertiary objective of this trial is to evaluate the biochemistry change of lipid profile change, myopathy, or liver enzyme change after the lipid lowering therapy.
|
up to 5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: C C W, chauchungwu@ntu.edu.tw
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200910021R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerotic Vascular Diseases
-
Advanced Education & Research CenterUniversity of Karachi; Pakistan Cardiac Society (Heart House)RecruitingAtherosclerotic Cardiovascular Diseases (ASCVD)Pakistan
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Pauls Stradins Clinical University HospitalActive, not recruitingAtherosclerotic Cardiovascular DiseaseLatvia
-
Novartis PharmaceuticalsNot yet recruitingElevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
-
University of Campania "Luigi Vanvitelli"IRCCS Multimedica; Cardarelli HospitalCompleted
-
Zibo Central HospitalUnknownAtherosclerosisChina
-
University of Wisconsin, MadisonCompleted
-
University Hospital MuensterWithdrawn
-
Kahramanmaras Sutcu Imam UniversityCompletedCoronary Artery Disease | Progression of Atherosclerotic PlaqueTurkey
-
Yuhan CorporationCompletedAcute Coronary Syndrome | Carotid Atherosclerotic Plaque With InflammationKorea, Republic of